Novogene Co (SHSE:688315) Other Current Liabilities: ¥730 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688315 Novogene Co Ltd SHSE:688315
85 GF Score
Price ¥16.02
GF Value ¥16.06
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Novogene Co Other Current Liabilities?

Novogene Co SHSE:688315 -1.11% 85 Other Current Liabilities is ¥730 Mil as of Mar. 2026. GuruFocus rates SHSE:688315 with a GF Score™ of 85/100 and a GF Value™ of ¥16.06 (Fairly Valued). The stock has 7 warning signs investors should review.

Novogene Co's other current liabilities for the quarter that ended in Mar. 2026 was ¥730 Mil.

Novogene Co's quarterly other current liabilities increased from Sep. 2025 (¥693 Mil) to Dec. 2025 (¥759 Mil) but then declined from Dec. 2025 (¥759 Mil) to Mar. 2026 (¥730 Mil).

Novogene Co's annual other current liabilities declined from Dec. 2023 (¥757 Mil) to Dec. 2024 (¥734 Mil) but then increased from Dec. 2024 (¥734 Mil) to Dec. 2025 (¥759 Mil).

Novogene Co Other Current Liabilities Related Terms

Novogene Co Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Novogene Co's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novogene Co Other Current Liabilities Chart

Novogene Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 613.70 727.28 756.91 733.86 759.02

Novogene Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 705.65 715.08 693.42 759.02 730.33
SHSE:688315
85GF Score
Novogene Co Ltd SHSE:688315
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novogene Co Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of ¥730 Mil mean?
Novogene Co (SHSE:688315) has a Other Current Liabilities of ¥730 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Novogene Co.
Is Novogene Co's Other Current Liabilities too high?
Novogene Co's current Other Current Liabilities is ¥730 Mil. Overall, Novogene Co has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Novogene Co's Other Current Liabilities compare to VRTX and REGN?
Novogene Co's Other Current Liabilities of ¥730 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Novogene Co. Novogene Co's current Other Current Liabilities is ¥730 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novogene Co stock overvalued right now?
Based on GuruFocus' analysis, Novogene Co (SHSE:688315) is currently considered Fairly Valued. The stock's GF Value™ is ¥16.06, compared to a current price of ¥16.02 — trading 0.2% below its estimated fair value. The current Other Current Liabilities is ¥730 Mil. Novogene Co's overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Novogene Co (SHSE:688315), the current Other Current Liabilities is ¥730 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novogene Co (SHSE:688315) Overvalued in 2026?

Based on GuruFocus' analysis, Novogene Co stock appears to be undervalued. The current stock price of ¥16.02 is trading 0.2% below its estimated GF Value™ of ¥16.06. GuruFocus considers Novogene Co to be Fairly Valued.

Key valuation signals for SHSE:688315:

  • Other Current Liabilities: ¥730 Mil
  • GF Value™: ¥16.06 vs. price of ¥16.02 (0.2% below fair value)
  • GF Score™: 85/100 with 7 warning signs

No single metric tells the full story. See the SHSE:688315 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novogene Co Business Description

Address No. 29, Shengshengyuan Road, Room B258, Innovation Building, Huilongguan Town, Changping District, Beijing, CHN, 100015
Novogene Co Ltd is engaged in providing multi-level scientific research and technical services and solutions for life science basic research, medical and clinical application research, and independent development and innovation of genetic testing medical equipment.
85GF Score

Get the complete analysis for SHSE:688315

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥16.02
Price
¥16.06
GF Value